natgillin/translations-raw huggingface dataset:
Machine as in claim 2, characterized in that actuator means (35) are associated with said mobile pin (33) and are suitable to move it to said operating position and non-operating position. 
Stroj prema zahtjevu 2, naznačen time da su sredstva za aktiviranje (35) povezana s navedenim pomičnim klinom (33) i pogodna su za njegovo pomicanje u navedeni radni položaj i neradni položaj.
The optical filter of claim 7, wherein the passband has a full width at half maximum (FWHM) of less than 50 nm. 
Optički filter prema zahtjevu 7, gdje propusni opseg posjeduje punu širinu na polovici maksimuma (FWHM) manju od 50 nm.
preparing argatroban monohydrate according to a method as defined in one of the claims 1-8; 
Pripreme argatroban monohidrata prema metodi definiranoj u zahtjevima 1-8;
Fig. 2a shows a cross-section of the central line section 32 of the line 13 with a first line part 30 and a second line part 31. 
Slika 21 prikazuje presjek središnjeg dijela 32 cijevi 13 s prvim dijelom cijevi 30 i drugim dijelom cijevi 31.
applying a first solution that optionally comprises poly(ethylene glycol) and sorbitol to a cation exchange chromatographic material, thereby equilibrating the material; 
- nanošenje prve otopine koja po potrebi obuhvaća poli(etilenglikol) 1 sorbitol za kationsku izmjenu kromatografskog materijala, te time uravnotežavanje materijala,
a heater to heat waste in the chamber; 
- > grijač za zagrijavanje otpada u komori;
A preferred delivery-enhancement agent comprises hyaluronidase which has been observed to very significantly increase delivery of therapeutic cells to the CNS when applied to the upper third of the nasal cavity as either a pretreatment to the therapeutic cell application of the present invention, or as a component of the pharmaceutical composition comprising therapeutic cells of the present invention. 
Terapijske stanice namijenjene upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačene time što se navedeno liječenje dodatno sastoji u primjeni u gornju trećinu nosne šupljine životinje najmanje jednog sredstva za poboljšavanje unosa u djelotvornoj količini u farmaceutski pripravak koji sadrži terapijske stanice, ili prije primjene terapijskih stanica.
IL-2 is naturally translated in humans as a precursor protein (e.g. 
IL-2 je kod ljudi prirodno preveden kao prekursor protein (na pr.
The pharmaceutical formulation of claim 11, wherein the therapeutic agent is an siRNA. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 11, pri čemu je terapijski agens siRNA.
The polypeptide according to claim 1, wherein said substitution of an amino acid by a corresponding non-natural amino acid is selected from the group consisting of: 
Polipeptid sukladno patentnom zahtjevu 1, naznačen time, da su navedene jedna ili više supstitucija aminokiseline odgovarajućom neprirodnom aminokiselinom odabrane iz skupine koju čine: ◦ supstitucije aminokiseline odgovarajućom 6 aminokiselinom;
The pharmaceutical composition of any one of claims 1-13, wherein the SAP polypeptide was expressed in a CHO cell. 
ekspresija SAP polipeptida u CHO stanici; i ii) izolaciju SAP polipeptida iz stanice.
SEQ ID NO. 2 or a portion thereof comprising (a). 
SEQ ID NO. 2 ili njen dio koji sadrži (a).
Components in the upper right hand part of Figure 2 are located in a operator cab. 
Komponente u gornjem desnom kutu slike 2 smještene su u kabini operatera.
A synergistic combination for use according to any one of the preceding claims, wherein the antibody specific for CD38 and melphalan are administered separately. 
Sinergistička kombinacija namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što se protutijelo specifično za CD38 i melfalan primjenjuje odvojeno.
The use of a composition comprising a dried, nonviable selenium-enriched yeast wherein the total selenium content of said yeast comprises two percent or less inorganic selenium in the manufacture of a medicament, wherein the medicament is formulated for administration to a subject under conditions such that the expression of a gene selected from the group consisting of Lhx8 and TGFB-2 is enhanced in said subject for the treatment of neurodegenerative disease selected from amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, multiple sclerosis, spinocerebellar ataxia, Friedreich's ataxia, and myotonic dystrophy. 
HR P20120337 T1 PATENTNI ZAHTJEVI Pripravak koji se koristi u proizvodnji lijeka sadrži suhi, neživi kvasac obogaćen selenom, naznačen time da u ukupnom sadržaju selena ima dva posto ili manje neorganskog selena, pri čemu je lijek formuliran za primjenu u subjektu pod uvjetom da se izražavanje komplement gena smanjuje u moždanoj kori tog subjekta u svrhu liječenja ili prevencije Alzheimerove bolesti.
The reaction was stirred for 16 hours at room temperature. 
Reakcija je miješana 16 sati na sobnoj temperaturi.
The compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrole (Z)-2-butenedioate according to claim 1 characterized in that the compound is in a orthorhombic crystal form which contains 10% or less of another crystalline form, 5% or less of another crystalline form, or no detectable amount of another crystalline form. 
Spoj trans-5-kloro-2,3,3a, 12b-tetrahidro-2-metil-1H-dibenz [2,3:6,7] oksepino [4,5-c] pirol (Z)-2-butendioat prema Zahtjevu 1, naznačen time, da je spoj ortorombskog kristalnog oblika koji sadržava 10% ili manje drugog kristalnog oblika, 5% ili manje drugog kristalnog oblika, ili količinu drugog kristalnog oblika koju se ne može odrediti.
The composition according to claim 14: 
Pripravak prema zahtjevu 12:
The microaggregation of IL-2 in the PROLEUKIN™ product is important for in vivo efficacy. 
Mikroagregacija IL-2 u proizvodu PROLEUKINTM je važna za učinkovitost in vivo.
The inhibitor of Dynamin 2 for use according to anyone of claims 1, 2, 3 and 4, wherein the dynamin 2 inhibitor is selected from the group consisting of an antibody directed against Dynamin 2, or a nucleic acid molecule interacting directly with a nucleic acid encoding Dynamin 2. 
Inhibitor dinamina 2, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1, 2, 3 i 4, naznačen time što se inhibitor dinamina 2 bira iz skupine koju čine protutijelo usmjereno protiv dinamina 2, ili molekula nukleinske kiseline koja izravno međudjeluje s nukleinskom kiselinom koja kodira dinamin 2.
German Patent Application Publication No. 
Broj europske prijave patenta:
The treatment and/or prevention method according to claim 33 or 34, characterized in that the abnormal bone metabolism is osteoporosis, bone destruction accompanying rheumatoid arthritis or bone destruction accompanying cancer metastasis to bone. 
Antitijelo ili njegov funkcionalni fragment za uporabu u skladu sa zahtjevom 21 ili 22, uporaba u skladu sa zahtjevom 23 ili 24, ili preparati za uporabu u skladu sa zahtjevom 25 ili 26, karakterizirani time da je abnormalni metabolizam kostiju osteoporoza, destrukcija kostiju koja prati reumatoidni artritis ili destrukcija kostiju koja prati metastaze raka u kostima.
The method according to Claim 1, wherein a compound comprising the compound (ii) adhered to the compound (i) is used as compounds (i) and (ii). 
Postupak prema zahtjevu 1, naznačen time, da se spoj koji sadrži spoj (1i) koji je priključen spoju (1), upotrebljava kao spoj (1) 1 spoj (ii).
A pharmaceutical composition comprising a therapeutically effective amount of a salt according to claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži terapeutski učinkovitu količinu soli u skladu sa zahtjevom 1 ili 2 1 farmaceutski prihvatljiv nosač.
A pharmaceutical or veterinary composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier. 
Farmaceutski ili veterinarski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 ili 2, kao i najmanje jednu farmaceutski prihvatljivu podlogu.
Preferably, the surfaces are polished after the pickling by using an electrolyte in a galvanic bath. This leads to a reduction of the surface roughness, i.e. in total to a smaller overall surface. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se, nakon jetkanja, površine poliraju elektrolitom u kadi za galvaniziranje.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule for use according to claim 22, wherein the one or more further therapeutic agents are selected from the group consisting of cisplatin, gefitinib, cetuximab, rituximab, bevacizumab, erlotinib, bortezomib, thalidomide, pamidronate, zoledronic acid, clodronate, risendronate, ibandronate, etidronate, alendronate, tiludronate, arsenic trioxide, lenalidomide, filgrastim, pegfilgrastim, sargramostim, suberoylanilide hydroxamic acid, and SCIO-469. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 22, naznačena time što je jedno ili više daljnjih terapijskih sredstava odabrano iz skupino koja se sastoji od cisplatina, gefitiniba, cetuksimaba, rituksimaba, bevacizumaba, erlotiniba, bortezomiba, talidomida, pamidronata, zoledronske kiseline, klodronata, porandronata, ibandronata, etidronata, alendronata, tiludronata, arsenovog trioksida, lenalidomida, filgrastima, pegfilgrastima, sargramostima, suberoilanilid- hidroksamične kiseline i SCIO-469.
Compound according to any one of the preceding claims, characterized in that the compound activates the target opioid receptor in conditions of inflammation-associated pH in inflamed tissue, preferably at pH values of 4, 4.5, 5, 5.5, 6 or 6.5, or any other pH value below 7. 
Spoj u skladu s prethodnim patentnim zahtjevom namijenjen upotrebi kao medikament, naznačen time što spoj aktivira ciljani opioidni receptor u uvjetima pH povezanog s upalom u upaljenom tkivu, gdje uvjeti pH povezanog s upalom pokazuju vrijednost pH ispod 7.
Fan unit according to claim 11, wherein the grooves are disposed in a star shape distributed around the circumference. 
Ventilatorska jedinica (1) prema zahtjevu 17 ili 18, naznačena time da su utori (36) raspoređeni po obodu u obliku zvijezde.
An additional grooved cellulose acetate filter piece of 8 mm length was inserted into the mouth end of the tube to give the appearance of a conventional cigarette. 
Dopunski nažljebljen filtar od acetata celuloze dužine 8 mm umetnut je u usni kraj cijevi da da izgled konvencionalne cigarete.
a pharmaceutically acceptable carrier or diluent. 
(b) farmaceutski prihvatljiv nosač ili razrjeđivač.
At neutral pH, hydrophobic capture occurs in HCIC resin by both an aliphatic-hydrophobic spacer and a neutral (uncharged) pyridine ring. 
Pri neturalnom pH do hidrofobnog hvatanja u smoli HCIC dolazi i preko alifatsko-hidrofobne razmaknice i neutralnog (nenabijenog) piridinskog prstena.
The present invention therefore relates to a conjugate comprising at least one compound carrying carboxyl groups and a linear or branched oligomer which consists of peptidically linked monomer units and which is either built up in total from more than 50% (based on the number of monomer units) of e-lysine monomer units or comprises at least 10 successive monomer units which are built up from at least 70% (based on the number of monomer units) of e-lysine monomer units. Preference is given to the use of compounds carrying carboxyl groups in which the proportion of the carboxyl groups in the molar mass of the compound carrying carboxyl groups is greater than 30%, particularly preferably greater than 40%. In a preferred embodiment, in particular for therapeutic applications, the conjugate additionally comprises at least one active compound, preferably covalently bonded. 
Konjugat koji sadrži najmanje jedan spoj koji nosi karboksilne skupine i oligomer koji se sastoji od peptidno vezanih lizinskih monomernih jedinica, gdje su gore spomenute jedinice lizinskih monomera u oligomeru u svakom slučaju povezane putem €g-amino skupine bočnog lanca, naznačen time što, i da u slučaju spoja koji nosi karboksilne skupine, udio karboksilnih skupina u molekularnoj težini spoja koji nosi karboksilne skupine je veći od 30%, time što barem jedan spoj koji nosi karboksilne skupine koji je konjugiran na oligomer sadrži dvije ili više slobodnih karboksilnih skupina, time što konjugat sadrži između 3 1 6 ili više od 9 spojeva koji nose karboksilne skupine po 10 monomernih jedinica, i time što oligomer ima duljinu lanca od 10 do 50 monomernih jedinica. Konjugat prema zahtjevu 1, naznačen time što je dodatno barem jedan aktivni spoj kovalentno vezan na konjugat.
Vigers et al., Nature. 
Vigers i sur., Nature.
The set of panels as recited in embodiment 15, wherein the separate material is covered with a foil. 
Komplet dijelova namještaja prema zahtjevu 11, naznačen time da je odvojeni materijal prekriven folijom.
The term “stable” as used herein in, for example the expression “a stable ET-743 formulation”, refers to a formulation that satisfies stability characteristics as reported herein and equivalents thereof, that are not possessed by conventional formulations and that are not achieved when the formulation is prepared by conventional manufacturing methodologies. 
Pojam "stabilan" kao što je ovdje korišten, npr. izraz "stabilan ET-743 oblik", odnosi se na oblik koji zadovoljava karakteristike stabilnosti kao što je ovdje prikazano i njene ekvivalente, koje ne posjeduju uobičajeni oblici i koje se ne postižu kada je oblik pripremljen uobičajenim metodologijama proizvodnje.
the anti-SNAP-25 antibody comprises a heavy chain variable region comprising CDRs comprising the amino acid sequences of at least one of SEQ ID NOs: 93, 96, and 100 and a light chain variable region comprising CDRs comprising the amino acid sequences of at least one of SEQ ID NOs: 105, 110, and 115. 
(ii) anti-SNAP-25 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži CDRs koje sadrže sekvence aminokiselina najmanje jedne od SEQ ID NOs: 93, 96 i 100 i varijabilnu regiju lakog lanca koja sadrži CDRs koji sadrže sekvence aminokiselina najmanje jedne od SEQ ID NOs: 105, 110i 115.
precipitating IgG from the supernatant with between about 20% and about 30% alcohol at a lower temperature and at a pH of between about 6.7 and about 7.3 to form a first precipitate, 
taloženje IgG iz sloja s površine s oko 20% do oko 30% alkohola na nižoj temperaturi i na pH-vrijednosti od oko 6,7 do oko 7,3, za tvorbu prvog taloga,
the serine at position 3 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, D, F, H, I, K, L, N, Q, R, T, V, W, or Y; 
serin na položaju 3 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, D, F, H, I, K, L, N, Q, R, T, V, W te Y;
A method for reducing pain associated with a GFRa3-related condition or disease, the method comprising administering the antibody or antigen-binding fragment of claim 1, to a patient in need thereof, wherein the pain associated with the condition or disease is ameliorated or reduced in severity or frequency of occurrence. The method of claim 6, wherein the antibody or antigen-binding fragment is administered to the patient in combination with a second therapeutic agent. 
Izolirano antitijelo ili njegov fragment koji vezuje antigen prema bilo kojem patentnom zahtjevu od 1 do 6 ili farmaceutski pripravak prema patentnom zahtjevu 10 ili 11, za primjenu u liječenju stanja ili oboljenja povezanog s GFRa3 ili bolova povezanih sa stanjem ili oboljenjem povezanim s GFRa3, naznačeno time, što se stanje ili oboljenje povezano s GFRa3 sprječava, ublažava ili smanjuje u pogledu ozbiljnosti ili učestalosti javljanja ili se bolovi povezani sa stanjem ili oboljenjem sprječavaju, ublažavaju ili smanjuju u pogledu ozbiljnosti ili učestalosti javljanja;
A composition according to claim 11 wherein the lubricant is sucrose stearate. 
Pripravak u skladu s patentnim zahtjevom 11, naznačen time što je mazivo saharozni stearat.
The use of a first therapeutic agent represented by the following structural formula: or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of Gaucher disease, wherein said treatment comprises administrating an effective amount of the first therapeutic agent in combination with an effective amount of a second therapeutic agent that is effective for treating Gaucher disease. 
O: ili njegova farmaceutski prihvatljiva sol, za proizvodnju lijeka naznačeno time da je za upotrebu za liječenje Gaucherove bolesti, pri čemu navedeno liječenje obuhvaća davanje učinkovite količine prvog terapijskog sredstva u kombinaciji s učinkovitom količinom drugog terapijskog sredstva koje je korisno za liječenje Gaucherove bolesti.
A peptide according to any one of claims 1 to 4, or a nucleic acid or expression vector according to claim 5 for use in medicine. 
Nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5 za uporabu u medicini.
A method for obtaining a HLA-A*2402-restricted epitope able to trigger an immune response against a HLA-A*2402-restricted cryptic epitope of an antigen, comprising the steps of 
HR P20161710 T1 PATENTNI ZAHTJEVI Metoda za dobivanje HLA-A*2402-restrikcijskog epitopa koji može potaknuti imuni odgovor protiv HLA-A*2402 restrikcijskog kriptičkog epitopa antigena, obuhvaća korake
In certain instances, in undesirable conditions for ocular boundary lubrication, such those resulting from aqueous or evaporative dry eye disease, Sjögren's syndrome, keratoconjunctivitis sicca, androgen deficiency, meibomian gland disease, estrogen replacement therapy, contact lens wear, refractive surgery, allergy, reduced tear film breakup time, allergy, ocular surface disorders, increased protease levels in the tear film and at the ocular surface, chronic inflammation, hyperosmolarity, and aging, a compromised tear film will exist. 
Farmaceutska kompozicija za primjenu prema patentnom zahtjevu 1, pri čemu nedostatak okularne lubrikacije je neželjena okularna granična lubrikacija koja nastaje od bolesti suhog oka uslijed nedostatka vodenog filma ili isparavanja, Sjogren-ovog sindroma, keratoconjunctivitis sicca, nedostatka androgena, bolesti meibomian žlijezda, zamjenske terapije estrogena, nošenja kontaktnih leća, refraktivne operacije, smanjenog vremena prekida suznog filma, alergije, poremećaja okularne površine, povećanih nivoa proteaze u suznom filmu i na okularnoj površini, kronične inflamacije, hiperosmolarnosti ili starenja.
R6a is hydrogen, or lower alkyl optionally substituted by substituent group C, and 
R je vodik, ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, i
the production of biobutanol, bioethanol or of both biobutanol and bioethanol. 
proizvodnju biobutanola i/ili bioetanola.
The compound of claim 1, wherein X is 1,2-ethane disulfonic acid. 
Spoj prema zahtjevu 1, naznačen time što X je bromovodična kiselina.
In a further embodiment of the disclosure, the pharmaceutical composition further comprises an immunosuppressive or anti-inflammatory agent. 
Farmaceutska smjesa iz Zahtjeva 17, naznačena time, što dalje sadrži imunosupresivno ili antiupalno sredstvo.
One preferred group of the compounds of Group A consists of those wherein R1 is hydrogen or methyl, R2 is methyl and Z is selected from the group consisting of 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethyl- phenyl, 4-trifluoromethyl-phenyl, 3,4-dichlorophenyl, 3-bromophenyl, 4-bromophenyl,4-methoxyphenyl and 3-trifluoromethyl-4-chloro-phenyl. 
Jedna poželjna skupina spojeva iz skupine A sastoji se od onih u kojima je R,; vodik ili metil, R» je metil, a Z se bira iz skupine koja sadrži 3-klorofenil, 4-klorofenil, 3-trifluorometilfenil, 4-trifluorometilfenil, 3,4-diklorofenil, 3-bromofenil, 4-bromofenil, 4-metoksifenil i 3-trifluorometil-4-klorofenil.
FIELD OF THE INVENTION The present invention relates to producing a flexible data sheet in a security document, such as a passport. 
Predmetni izum se odnosi na izradu lista za podatke koji se može pregibati u sigurnosnom dokumentu, takvom kao što je putovnica.
An antibody-drug conjugate (ADC) for use in a method for treating a cancer, reducing tumor growth and/or causing tumor regression in a patient, the ADC comprising an antibody or antigen-binding fragment thereof and a cytotoxin, wherein the antibody or antigen-binding fragment of the ADC specifically binds EGFRvIII but does not bind the junctional peptide of SEQ ID NO:148 or the peptide of SEQ ID NO:165, and wherein the antibody or fragment thereof comprises a combination of HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 amino acid sequences of SEQ ID NOs: 36/38/40/44/46/48, and the method comprises administering to a patient in need thereof the ADC. 
Konjugat antitijela i lijeka (engl. antibody-drug conjugate, ADC) za primjenu u metodi za liječenje raka, koji smanjuje rast tumora i/ili izaziva regresiju tumora kod pacijenta, pri čemu ADC obuhvaća antitijelo ili njegov fragment koji se vezuje za antigen i citotoksin, naznačeno time, što se antitijelo ili njegov fragment koji se vezuje za antigen iz ADC-a specifično vezuje za EGFRYIII, ali se ne vezuje za zglobni peptid sa SEQ ID NO:148 ili peptid sa SEQ ID NO:165, 1 naznačeno time, što antitijelo ili njegov fragment obuhvaća kombinaciju aminokiselinskih sekvenci HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3 sa SEQ ID NO: 36/38/40/44/46/48, a metoda obuhvaća primjenu ADC-a kod pacijenta kojemu je potreban.
New York, Wiley 1979, 260-348), metallic ions and metallorganic compounds as mercury and methylmercury (Bolger P M, Schwetz B A, N Engl J Med 2002; 347, 1735), and many other marine pollutants, all clearly noxious to health if ingested as food and/or as drug. 
New York, Wiley 1979, 260-348), metalni ioni i organometalni spojevi kao što su živa i metilživa (Bolger PM, Schwetz BA, N Engl J Med 2002; 347, 1735), kao i mnogi drugi morski zagađivači, HR P20080415 T3 svi jasno štetni za zdravlje ako se progutaju kao hrana i/ili kao lijek.
In the closed state the jaw members tightly enclose a capsule space. 
U zatvorenom položaju elementi čeljusti čvrsto obuhvaćaju prostor za čahuru.
the preparation b has at least 1% of collagens, elastins, keratins, fibronectins, actins, myosins, laminins, peptides, hydrolysed, fibrillated or not, or chemically modified collagens, elastins, keratins, fibronectins, actins, myosins, laminins, peptides, hydrolyzed, fibrillated or not with PA or with Pre-polymer of polyhydroxyurethanes terminated by amines functions (PRE-PA) or a blend of those constituents in a blend containing acceptable solvents and optionally PA monomers of PHU or PRE-PA or a blend of PRE-PA and PA to ensure that the preparation b contains amine functions from polyamines. 
pripravak b ima barem 1 % kolagena, elastina, keratina, fibronektina, aktina, miozina, laminina, peptida, hidroliziranih, fibriliranih ili ne, ili kemijski modificiranih kolagena, elastina, keratina, fibronektina, aktina, miozina, laminina, peptida, hidroliziranih, fibriliranih ili ne s PA ili s Pre-polimerom polihidroksiuretana terminiranog funkcijama amina (PRE-PA) ili mješavinu spomenutih sastojaka u mješavini koja sadrži prihvatljiva otapala 1 izborno PA monomere od PHU ili PRE-PA ili mješavinu PRE-PA 1 PA kako bi se osiguralo da pripravak b sadrži funkcije amina od poliamina.
the full-length heavy chain comprises SEQ ID NO:28 and the full-length light chain comprises SEQ ID NO:58, 
puni teški lanac ima SEQ ID NO:28, a puni laki lanac ima SEQ ID NO:58.
The management system as claimed in claim 5, wherein said at least one sensor transmits measurements to said computing means in a wired or wireless manner. 
Sustav upravljanja prema zahtjevu 5, naznačen time da navedeni najmanje jedan senzor (24) odašilje mjerenja navedenim računalnim sredstvima putem žičnog ili bežičnog načina.
at least one needle affixed to an outer surface of the balloon member; 
najmanje jednu preinaku koja osigurava stabilnost molekule RNA;